Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590758 | 0.90 | ADORA2A (0.79) | ADORA2A | |
| SCHEMBL8242529 | 0.88 | ADORA2A (0.70) | ADORA2AITK | |
| SCHEMBL8249626 | 0.88 | ADORA2A (0.68) | ADORA2A | |
| SCHEMBL8245643 | 0.88 | ADORA2A (0.80) | ADORA2AITK | |
| SCHEMBL8246370 | 0.88 | ADORA2A (0.69) | ADORA2AITK | |
| SCHEMBL8246338 | 0.87 | ADORA2A (0.63) | ADORA2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL8246921 | 0.87 | ADORA2A (0.67) | ADORA2A | |
| SCHEMBL8240655 | 0.86 | ADORA2A (0.65) | ADORA2A | |
| SCHEMBL8247597 | 0.86 | ADORA2A (0.79) | ADORA2A | |
| SCHEMBL8249504 | 0.85 | ADORA2A (0.65) | ADORA2AITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146536-A1 | 2-Aminoimidazopyridines for treating neurodegenerative diseases | PHARMACOPEIA, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2007022305-A2 | 2-AMINOIMIDAZOPYRIDINES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146536-A1 | 2-Aminoimidazopyridines for treating neurodegenerative diseases | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885KDM4E 3341/4885ALDH1A1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.